Jose Baselga - AstraZeneca PLC President
| AZN Stock | USD 71.20 0.35 0.49% |
President
Dr. Jose Baselga, M.D. Ph.D., serves as Executive Vice President Research Development Oncology of the Company. He joined AstraZeneca in January 2019 as Executive VicePresident, RD Oncology and is responsible for the oncology portfolio from discovery through to latestage development. He was formerly PhysicianinChief at Memorial Sloan Kettering Cancer Center, which became the leader in earlyphase clincial trials for cancer therapies and diagnostic genetic sequencing under his leadership. In addition, he was Professor of Medicine at Weill Cornell Medical College and President of the American Association for Cancer Research . Jose is an international thought leader on innovation in cancer care and clinical research. His work has led to the approval of lifesaving cancer therapies and the creation of several biopharmaceutical companies. Jose is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and an elected Fellow of the AACR Academy. He is a past President of the European Society for Medical Oncology and recently received their Lifetime Achievement Award. He serves on the Board of Directors of the American Society of Clinical Oncology and AACR. since 2019.
| Age | 58 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Address | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Tangible Asset Value is very stable compared to the past year. As of the 24th of April 2024, Intangibles To Total Assets is likely to grow to 0.60, while Total Current Assets are likely to drop about 15.3 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Karen Santiago | Bristol Myers Squibb | 50 | |
| Taiyin Yang | Gilead Sciences | 59 | |
| Jan Lundberg | Eli Lilly and | 63 | |
| Philip Thomson | GlaxoSmithKline PLC ADR | N/A | |
| Paul Carter | Gilead Sciences | 54 | |
| CA BSc | GlaxoSmithKline PLC ADR | 58 | |
| Elias Zerhouni | Sanofi ADR | 65 | |
| Anat Hakim | Eli Lilly and | 51 | |
| James Bradner | Novartis AG ADR | 49 | |
| Paul Autenried | Bristol Myers Squibb | 59 | |
| John Reed | Sanofi ADR | 60 | |
| Abbas Hussain | GlaxoSmithKline PLC ADR | N/A | |
| Anne Nielsen | Bristol Myers Squibb | 55 | |
| James Meyers | Gilead Sciences | 51 | |
| Michael Goettler | Pfizer Inc | 50 | |
| Jyoti Mehra | Gilead Sciences | 48 | |
| Andrew Cheng | Gilead Sciences | N/A | |
| Jeffrey Stewart | AbbVie Inc | 55 | |
| Freda LewisHall | Pfizer Inc | 63 | |
| Patrick Vallance | GlaxoSmithKline PLC ADR | 57 | |
| Luke Miels | GlaxoSmithKline PLC ADR | 49 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.066 |
AstraZeneca PLC ADR Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, Chief Financial Officer, Executive Director | ||
| Sherilyn McCoy, Non-Executive Independent Director | ||
| Genevieve Berger, Non-Executive Independent Director | ||
| Luke Miels, Executive Vice-President GPPS | ||
| Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development | ||
| Paul Hudson, Executive Vice President North America | ||
| Nazneen Rahman, Non-Executive Independent Director | ||
| Jose Baselga, Executive Vice President - Research & Development Oncology | ||
| JeanPhilippe Courtois, Non-Executive Independent Director | ||
| Deborah Eldracher, Non-Executive Independent Director | ||
| Thomas Larsen, IR Contact Officer | ||
| Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer | ||
| Tony Mok, Non-Executive Independent Director | ||
| Mark Mallon, Executive Vice President International | ||
| Fiona Cicconi, Executive Vice President - Human Resources | ||
| Deborah DiSanzo, Non-Executive Independent Director | ||
| Chris Sheldon, Head Relations | ||
| Shriti Vadera, Non-Executive Independent Director | ||
| Leif Johansson, Non-Executive Independent Chairman of the Board | ||
| Leon Wang, Executive Vice President - International and China President | ||
| Ann Cairns, Non-Executive Director | ||
| Adrian Kemp, Company Secretary | ||
| Cornelia Bargmann, Non-Executive Director | ||
| Susan MD, Executive Development | ||
| Tim JacksonSmith, Non-Executive Director | ||
| Michel Demare, Non-Executive Independent Director | ||
| Graham Chipchase, Senior Non-Executive Independent Director | ||
| David Smith, Executive VP of Operations and Information Services | ||
| Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| Baroness Vadera, Non-Executive Independent Director | ||
| MBA DVM, CEO Director | ||
| Aradhana MD, CFO Director | ||
| Philip Broadley, Non-Executive Independent Director | ||
| Narayan Seshadri, Independent Director | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President, BioPharmaceuticals Business | ||
| David Fredrickson, Executive Vice-President Global Head Oncology Business Unit | ||
| Gonzalo Vina, Head Relations | ||
| Andrew Barnett, Head Relations | ||
| Bahija Jallal, Executive Vice President MedImmune | ||
| Rudolph Markham, Non-Executive Independent Director | ||
| Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals | ||
| Weiying Wang, Non-Executive Director | ||
| Bruce Burlington, Non-Executive Independent Director | ||
| Marcus Wallenberg, Non-Executive Director | ||
| Iskra Reic, Executive Vice President - Europe and Canada |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.066 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 133.64 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Shares Owned By Institutions | 16.83 % | ||||
| Number Of Shares Shorted | 7.66 M | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 5.46 X |
AstraZeneca PLC Investors Sentiment
The influence of AstraZeneca PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in AstraZeneca. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to AstraZeneca PLC's public news can be used to forecast risks associated with an investment in AstraZeneca. The trend in average sentiment can be used to explain how an investor holding AstraZeneca can time the market purely based on public headlines and social activities around AstraZeneca PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
AstraZeneca PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for AstraZeneca PLC's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average AstraZeneca PLC's news discussions. The higher the estimated score, the more favorable is the investor's outlook on AstraZeneca PLC.
AstraZeneca PLC Implied Volatility | 65.85 |
AstraZeneca PLC's implied volatility exposes the market's sentiment of AstraZeneca PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if AstraZeneca PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that AstraZeneca PLC stock will not fluctuate a lot when AstraZeneca PLC's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AstraZeneca PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AstraZeneca PLC's short interest history, or implied volatility extrapolated from AstraZeneca PLC options trading.
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving against AstraZeneca Stock
| 0.55 | ZURA | Zura Bio Limited Financial Report 10th of May 2024 | PairCorr |
| 0.52 | EFTR | Effector Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.44 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.059 | Dividend Share 2.9 | Earnings Share 1.91 | Revenue Per Share 2.4547 | Quarterly Revenue Growth 0.073 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.